

1 **Title**

2 **Plasma zinc status and hyperinflammatory syndrome in hospitalized**
3 **COVID-19 patients: an observational study**

4

5 **Authors:** Gil Verschelden^{1*}, Maxim Noeparast^{2,3*}, Maryam Noparast⁴, Mailis
6 Lauwers⁵, Charlotte Michel⁶, Frédéric Cotton⁷, Cleo Goyvaerts⁷, Maya Hites¹.

7 * Shared first authors

8

- 9 1. Clinic of Infectious Diseases, Cliniques Universitaires de Bruxelles (CUB),
10 Erasme Hospital, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
- 11 2. Institute of Molecular Oncology, Member of the German Center for Lung
12 Research (DZL), Philipps University, 35043 Marburg, Germany
- 13 3. Fonds Wetenschappelijk Onderzoek (FWO) – Vlaanderen
- 14 4. Department of Urologic Sciences, University of British Columbia, Vancouver,
15 BC, Canada.
- 16 5. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de
17 Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels,
18 Belgium
- 19 6. Department of Microbiology, Laboratoire Hospitalier Universitaire de
20 Bruxelles (LHUB-ULB), Brussels, Belgium
- 21 7. Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de
22 Bruxelles (LHUB-ULB), Université Libre de Bruxelles (ULB), Brussels,
23 Belgium
- 24 8. Laboratory for Molecular and Cellular Therapy (LMCT), Vrije Universiteit
25 Brussel (VUB), 1090 Brussels, Belgium

26

27 **Corresponding authors:** Gil.Verschelden@erasme.ulb.ac.be,
28 Maxim.Noeparast@staff.uni-marburg.de, and Maya.Hites@erasme.ulb.ac.be

29

30 **Abstract**

31 Deficiency of the element zinc is associated with cytokine releasing syndrome (CRS)
32 and the related acute respiratory distress syndrome as well as impaired antiviral
33 response. Similar complications associate with severe SARS-CoV-2.

34

35 We conducted a prospective, single-center, observational study in a tertiary
36 university hospital (CUB-Hopital Erasme, Brussels) to address the zinc status, the
37 association between the plasma zinc concentration, development of CRS, and the
38 clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.

39 One hundred and thirty-nine eligible patients were included between May 2020 and
40 November 2020 (median age of 65 years [IQR, 54 to 77]).

41 Our cohort's mean plasma zinc concentration was 56.2 µg/dL (standard deviation
42 [SD], 14.8) compared to 75.7 µg/dL (SD = 18.9 µg/dL) in the retrospective non-
43 COVID-19 control group (N = 1513; $P < .001$). Markedly, the absolute majority of
44 patients (96%) were zinc deficient (<80 µg/dL).

45 The mean zinc concentration was lower in patients with CRS compared to those
46 without CRS (-5 µg/dL; 95% CI, -10.5 to 0.051; $P = 0.048$).

47 Among the tested outcomes, zinc concentration is significantly correlated with only
48 the length of hospital stay ($\rho = -0.19$; $P = 0.022$), but not with mortality or
49 morbidity. As such, our findings do not support the role of zinc as a robust prognostic
50 marker among hospitalized COVID-19 patients who in our cohort presented high
51 prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as
52 a biomarker for assessing the risk of developing a tissue-damaging CRS and

53 predicting outcomes in patients diagnosed with COVID-19 at the early stage of the
54 disease.

55

56 **Keyword:** SARS-CoV-2, COVID-19, Zinc, cHIS, inflammation

57

58 **Main text**

59 **Introduction**

60 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with
61 significant mortality and morbidity in a subgroup of patients who develop cytokine
62 release syndrome (CRS) and the related acute respiratory distress syndrome
63 (ARDS)^{1,2}.

64

65 Zinc is the second most abundant common trace mineral in humans, yet ~20% of the
66 global population is estimated to suffer from different degrees of zinc deficiency³.

67 Precedent evidence suggests that zinc deficiency also can be associated with lung-
68 damaging complications such as ARDS^{4,5} as well as impaired antiviral response^{3,6-9}.

69 For instance, zinc deficiency has shown to be associated with excessive TNF- α and IL-
70 6 activity, factors known to have a significant role in CRS^{9,10}.

71 However, the zinc status and its association with SARS-CoV-2 remains unknown.

72

73 Herein, we designed a study to determine the zinc status, explored the association
74 between the plasma zinc concentration, the development of CRS, and the clinical
75 outcomes in hospitalized COVID-19 patients.

76

77 **Methods**

78 We conducted a prospective, single-center, observational study in a tertiary
79 university hospital (CUB-Hôpital Erasme, Brussels) between May 2020 and
80 November 2020. Consecutive hospitalized adult patients with PCR-confirmed SARS-
81 CoV-2 infection were enrolled after obtaining informed consent. We performed
82 clinical and laboratory assessments within 72 hours of admission. An atomic
83 absorption spectroscopy technique was used to measure zinc concentrations in the
84 plasma¹¹.

85 Plasma zinc concentrations of COVID-19 patients were compared with our
86 retrospective cohort of 1513 adult non-COVID-19 patients whose plasma zinc was
87 previously measured in our center. The patients were selected regardless of gender or
88 comorbidity during 2018.

89

90 The severity of COVID-19 was assessed daily during the course of hospitalization
91 using the WHO 10-point system¹².

92 Individual inflammatory parameters were assessed and summed on the day of
93 patients' study inclusion according to an additive six-point clinical scale, developed
94 and validated by Webb et al.¹³, to determine the presence and severity of COVID-19-
95 associated hyperinflammatory syndrome (cHIS)¹¹. Although the authors reported an
96 excellent discrimination¹⁴ of the maximum daily cHIS score for both in-hospital
97 mortality and mechanical ventilation, external validation was still lacking. As part of
98 this study, we independently evaluated the relevance of the cHIS scoring system and
99 determined the best cut-offs in our cohort.

100

101 We defined the clinical outcomes as the length of hospitalization, the incidence of
102 mechanical ventilation (including invasive and non-invasive ventilation), and

103 mortality. We recorded the outcomes with a follow-up of 90 days from hospital
104 admission.

105

106 **Baseline characteristics and patients' outcomes**

107 One hundred and thirty-nine eligible patients were included. The patient
108 characteristics and laboratory assessments are summarized in Table and Figure 1.

109

110 The participants were predominantly male (91/139, 65%) with a median age of 65
111 years (interquartile range [IQR], 54 to 77). Ninety-six patients (69%) had two or
112 more comorbidities. The median body mass index (BMI) was 27 kg/m² and 93/135
113 (69%) patients had a BMI >25 kg/m², among which 41/135 (30%) patients were
114 considered obese (BMI >30 kg/m²). The median time from symptoms onset to
115 inclusion was eight days (IQR, 6 to 12).

116 The median worst daily WHO severity score was 4 (IQR, 4 to 6). Forty-two patients
117 (30%) required mechanical ventilation or deceased during their hospitalization
118 (WHO score >5, severe COVID-19)¹⁰.

119 Nineteen patients (14%) were admitted to the intensive care unit (ICU) during their
120 hospital stay. Twenty patients (14%) deceased within 90 days of admission, of whom
121 seven (35%) had been admitted to ICU.

122

123 **Zinc status and its association with patients' outcomes**

124 The mean plasma zinc concentration in our cohort was 56.2 µg/dL (SD = 14.8)
125 compared to 75.7 µg/dL (SD = 18.9 µg/dL) in the control group. An unpaired t-test
126 with unequal variance (Welch's t-test) confirms that this difference is significant (*P*
127 <.001).

128 Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient
129 (<80µg/dL).

130

131 We observed that the plasma zinc concentration is weakly but significantly correlated
132 ($\rho = -0.19$; $P = 0.022$) with the length of hospital stay. However, the plasma zinc
133 concentration was not significantly associated with the risk of mortality or morbidity
134 (Table 2b). Still, the mean plasma zinc levels were systematically lower in
135 mechanically ventilated- compared to non-mechanically ventilated COVID-19 cases (-
136 5.23 µg/dL; 95% confidence interval [CI], -10.57 to 0.13; $P = 0.058$), and in dead
137 compared to surviving participants (-6.68 µg/dL; 95% CI, -13.68 to 0.33; $P = 0.065$).

138

139 **External validation of the cHIS score as the measure of inflammatory** 140 **status**

141 The area under the receiver operating characteristic curve (AUROC) for mechanical
142 ventilation and mortality was 0.687 and 0.674, respectively, which indicates a lack of
143 discrimination capacity ($AUC \leq 0.7^{14}$). Nevertheless, according to the results of the
144 Hosmer-Lemeshow goodness of fit test¹⁴, the score demonstrated a good calibration
145 (p-value > 0.05), with p-values of 0.681 and 0.649 for mechanical ventilation and
146 mortality, respectively.

147 Next, we aimed to identify a cHIS cut-off, which corresponds to CRS, to define a
148 binary (low- and high-risk for poor outcome) patient group regarding inflammatory
149 status. Our data corroborate with the cut-off suggested by Webb et al.¹¹,
150 demonstrating the best performance (Youden's J statistic closest to one) at a
151 threshold of $\geq 2^{15}$.

152 In our cohort, 74/134 (55%) patients had a cHIS score ≥ 2 . Importantly, greater
153 proportions of these cases needed mechanical ventilation (30/74, 40%) and died

154 (16/74, 22%) compared to patients with cHIS scores < 2 (11/60, 18%; $P = 0.006$) and
155 (4/60, 7%; $P = 0.013$) respectively.

156

157 Although our results support the association of CRS with both severe COVID-19 and
158 mortality, unlike Webb et al., we were not able to demonstrate an excellent
159 discrimination capacity of the cHIS score in our cohort¹³. In contrast to that study,
160 most of our patients (108/139, 78%) had received immunomodulatory or suppressive
161 therapies just before the laboratory evaluation (as part of our standard of care and
162 based upon WHO guidelines and findings of the Recovery trial¹⁶). Dexamethasone
163 reduces CRS and improves the outcome while inevitably lowers the cHIS score¹⁶. The
164 cHIS score is probably more appropriate to identify high-risk patients in ambulatory
165 practice or among the hypoxemic and dexamethasone-naïve patients.

166

167 **Association of plasma zinc concentration and cHIS score**

168 We were not able to show a significant association between plasma zinc levels and the
169 development of CRS (defined as cHIS score ≥ 2) in our cohort.

170 The mean concentration of plasma zinc was lower in patients with CRS compared to
171 those without CRS (-5 $\mu\text{g}/\text{dL}$; 95% CI, -10.5 to 0.051; $P = 0.048$). However, with
172 stringent and conservative Bonferroni adjustment, the results were not statistically
173 significant.

174

175 **Discussion and limitations of the study**

176 The small sample size and lack of a comparable control group (hospitalized for other
177 reasons than COVID-19) are the major limitations.

178 Additionally, as the absolute majority of the patients were zinc deficient, no room was
179 left for any comparison between zinc deficient and non-existing zinc sufficient
180 patients.

181

182 **Conclusions**

183 To the best of our knowledge, we report for the first time that an absolute majority of
184 hospitalized COVID-19 patients are zinc deficient.

185 We find a weak (reverse) correlation between plasma zinc concentration and the
186 length of hospital stay, but not with mortality or morbidity.

187 We independently validated cHIS as a score of COVID-19 severity, but we found no
188 significant association between zinc plasma concentration and cHIS among patients
189 who are almost all zinc deficient.

190 As such, our findings do not support the role of zinc as a robust prognostic factor
191 among hospitalized COVID-19 patients.

192 We recommend zinc to be measured prospectively in a larger, non-COVID-19
193 population to assess the incidence of the disease and CRS occurrence and its related
194 outcomes in zinc-deficient versus zinc-sufficient individuals.

195 We encourage further studies to explore the role of zinc as a biomarker for assessing
196 the risk of developing a tissue-damaging CRS and predicting outcomes in patients
197 diagnosed with COVID-19.

198

199 **Abbreviations**

200	ARDS	Acute respiratory distress syndrome
201	AUROC	Area under the receiver operating characteristic curve
202	BMI	Body mass index
203	cHIS	COVID-19-associated hyperinflammatory syndrome

204	CI	Confidence interval
205	CRS	Cytokine release syndrome
206	ICU	Intensive care unit
207	IQR	Interquartile range
208	SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
209	SD	Standard deviation

210

211 **Ethics approval and consent to participate**

212 Informed consent was obtained from all participants. The study was approved by the
213 ethics committee of Erasme Hospital, EC identifier P2020/261.

214

215 **Availability of data and materials**

216 The datasets used and/or analysed during the current study are available from the
217 corresponding author on reasonable request.

218

219 **Conflict of interest and funding:** We hereby confirm that there is no conflict of
220 interest associated with this publication and that this work did not receive any
221 financial support that could have influenced its outcome.

222

223 **Author contributions**

224 G.V and M.Noep: conceived the idea, co-authored the research proposal, designed
225 the study, analyzed the data, interpreted the results, generated the tables, and co-
226 authored the manuscript. G.V: medical consultation and handling the patients'
227 material. M.Noep: supervised the study design and the statistical analyses and
228 critically revised and contributed to drafting the manuscript. M.L, C.M, F.C: handled
229 the patients' material and performed the laboratory assessments. C.G: contributed to

230 drafting the research proposal and study design. M.H: supervised all stages of the
231 study, including the proposal and the study design, and critically revised and
232 contributed to drafting the manuscript. All authors revised and approved the
233 manuscript.

234

235 **Acknowledgments**

236 Special thanks to Prof.Dr. Frédérique Jacobs (Université Libre de Bruxelles, Erasme
237 Hospital).

238

239 **References**

- 240 1. Leisman, D. E. *et al.* Cytokine elevation in severe and critical COVID-19: a
241 rapid systematic review, meta-analysis, and comparison with other
242 inflammatory syndromes. *Lancet. Respir. Med.* **8**, 1233–1244 (2020).
- 243 2. Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. & Sekhon, M. S.
244 Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm
245 syndrome. *Eur. Respir. J.* **56**, 2003006 (2020).
- 246 3. Read, S. A., Obeid, S., Ahlenstiel, C. & Ahlenstiel, G. The Role of Zinc in
247 Antiviral Immunity. *Adv. Nutr.* **10**, 696–710 (2019).
- 248 4. Boudreault, F. *et al.* Zinc deficiency primes the lung for ventilator-induced
249 injury. *JCI insight* **2**, (2017).
- 250 5. Wessels, I. *et al.* Zinc supplementation ameliorates lung injury by reducing
251 neutrophil recruitment and activity. *Thorax* **75**, 253–261 (2020).
- 252 6. Asl, S. H., Nikfarjam, S., Majidi Zolbanin, N., Nassiri, R. & Jafari, R.
253 Immunopharmacological perspective on zinc in SARS-CoV-2 infection. *Int.*
254 *Immunopharmacol.* **96**, 107630 (2021).
- 255 7. Noeparast, A.; Verschelden, G.; Degeyter, D.; Marco, M.; Goyvaerts, C.; Hites,

- 256 M. In Light of the SARS-CoV-2 Pandemic: Revisit of the Evidence Associating
257 Zinc and Anti-viral Response. Preprints 2020, 2020040094. In Light of the
258 SARS-CoV-2 Pandemic: Revisit of the Evidence Associating Zinc and Anti-viral
259 Response. *Preprints* **2020040094**, (2020).
- 260 8. Prasad, A. S. Zinc in human health: effect of zinc on immune cells. *Mol. Med.*
261 **14**, 353–357 (2008).
- 262 9. Prasad, A. S. *et al.* Zinc supplementation decreases incidence of infections in
263 the elderly: effect of zinc on generation of cytokines and oxidative stress. *Am.*
264 *J. Clin. Nutr.* **85**, 837–844 (2007).
- 265 10. Mehta, P. *et al.* COVID-19: consider cytokine storm syndromes and
266 immunosuppression. *Lancet (London, England)* (2020) doi:10.1016/S0140-
267 6736(20)30628-0.
- 268 11. Davies, I. J., Musa, M. & Dormandy, T. L. Measurements of plasma zinc. I. In
269 health and disease. *J. Clin. Pathol.* **21**, 359–363 (1968).
- 270 12. A minimal common outcome measure set for COVID-19 clinical research.
271 *Lancet. Infect. Dis.* **20**, e192–e197 (2020).
- 272 13. Webb, B. J. *et al.* Clinical criteria for COVID-19-associated hyperinflammatory
273 syndrome: a cohort study. *Lancet. Rheumatol.* **2**, e754–e763 (2020).
- 274 14. Hosmer, D. W. & Lemeshow, S. *Applied Logistic Regression Second Edition.*
275 *Applied Logistic Regression* (2004).
- 276 15. YODEN, W. J. Index for rating diagnostic tests. *Cancer* **3**, 32–35 (1950).
- 277 16. Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N.*
278 *Engl. J. Med.* **384**, 693–704 (2021).
- 279
- 280

Table 1: Characteristics of study cohort (N=139)	No. Available	Value
Age (yr), median [IQR]	139	65 [54-77]
Gender - N (%)	139	
Female		48 (34)
Male		91 (65)
BMI (kg/m²), median [IQR]	135	27,2 [23-48]
Overweight (BMI≥25)		52 (38)
Obese (BMI≥30)		41 (30)
Smoking status, N (%)		
Never		97 (70)
Former		35 (25)
Current		7 (5)
Number of coexisting conditions, N (%)	139	
0		5 (4)
1		19 (14)
2		19 (14)
>2		96 (69)
Coexisting conditions, N (%)	139	
Hypertension		90 (65)
Diabetes		50 (36)
Hypercholesterolemia		54 (39)
Obstructive sleep apnea syndrome		11 (8)
Obstructive lung diseases		25 (18)
Coronary artery disease		19 (14)
Congestive heart failure		23 (16)
Atrial fibrillation		14 (10)
Chronic liver disease		4 (3)
Chronic kidney disease		31 (22)
Malign neoplasm		9 (6)
Immune suppression		25 (18)
Neurological nonvascular		12 (9)
Stroke		8 (6)
Days with symptoms before inclusion, median [IQR]	131	8 [6-12]
Days of hospitalization before inclusion, median [IQR]	139	1 [1-2]
COVID-19 medical therapy before inclusion	139	108 (78)
Hydroxychloroquine		9 (6)
Dexamethasone		99 (71)
Severity of COVID-19 (worst WHO score)	139	
Median WHO score [IQR]		4 [4-6]
With score >5 (severe disease), N (%)		42 (30)
cHIS score at inclusion	134	
Median [IQR]		2 [1-2]
With cHIS score ≥2, N (%)		74 (55)
Plasma zinc (Normal range: [80-120µg/dL])	139	
Mean level (SD)		56.2 (14.8)
With zinc deficiency, N (%)		133 (96)

Note: IQR = interquartile range, CI = confidence interval, OR = odds ratio

Table 2a: Outcomes at 90-days (N=139)

	Value
Length of hospital stay (days), median [IQR]	8 [5-13]
Mechanical ventilation, N (%)	42 (30)
ICU admission, N (%)	19 (14)
Deceased, N (%)	20 (14)

Table 2b: Association of outcomes and plasma zinc level (N=139)

	Value
Length of hospital stay and zinc level	Correlation coefficient (95% CI) = -0.19 (-0.35-0.03), $p = 0.022^{**}$
Mechanical ventilation and zinc level	OR (95% CI) = 0.98 (0.95-1.00), $p = 0.058^{***}$
Mortality and zinc level	OR (95% CI) = 0.97 (0.94-1.00), $p = 0.065^{***}$

Note:
 IQR = interquartile range, CI = confidence interval, OR = odds ratio
 $**$ Spearman correlation
 $***$ Logistic regression

